ASX Announcement

ASX : ENP

9 November 2026

Global IP Portfolio Expanded with Grant of South African Patent to 2043

- **South African patent granted for proprietary psilocin crystalline forms, further strengthening the Company's international intellectual property (IP) portfolio**
- **Follows the grant of a corresponding Australian patent, extending protection for Entropy's proprietary psilocin formulation technology into an additional jurisdiction**
- **Patent protection extends to September 2043, supporting the long-term development and commercialisation potential of the Company's proprietary psilocin technologies**
- **Strengthens the IP portfolio underpinning Entropy's TRP-8803 development program, complementing the Company's proprietary precision-controlled IV psilocin delivery technology**
- **Expanding international patent portfolio provides a stronger foundation for future clinical development, licensing and strategic partnership opportunities**
- **Expanding IP portfolio now spans granted patents in Australia and South Africa, with international applications progressing across formulations, dosing methods and therapeutic indications**

Melbourne, Australia – Entropy Neurodynamics Limited ('**Entropy**' or the '**Company**') (**ASX: ENP**), a clinical-stage biotechnology company developing precision-controlled psychedelic therapies, is pleased to advise that it has secured a South African patent covering proprietary crystalline forms of psilocin, further expanding the Company's international intellectual property portfolio and strengthening the broader IP position supporting its TRP-8803 development program.

The patent, titled *"Psilocin Crystalline Forms"* (Patent No. 2025/03086), follows the grant of a corresponding Australian patent (Patent No. 2023343417) earlier in 2026. The patent covers crystalline forms of psilocin, the active metabolite of psilocybin, and associated pharmaceutical compositions and methods of preparation. These crystalline forms offer improved stability, solubility and consistency compared with conventional psilocin formulations, addressing important considerations in the development and manufacture of pharmaceutical-grade therapeutics.

The latest grant complements Entropy's existing IP portfolio supporting TRP-8803, the Company's proprietary precision-controlled IV psilocin treatment platform. While the TRP-8803 platform is focused on the controlled administration of psilocin, the newly granted patent provides protection for specific crystalline forms and associated pharmaceutical formulations, further broadening the Company's IP position across complementary aspects of psilocin-based drug development.



Entropy's broader IP portfolio now includes granted Australian patents covering its proprietary precision-controlled IV dosing methodology and psilocin crystalline forms, together with South African patents protecting fibromyalgia treatment methods and, following this latest grant, crystalline psilocin formulations.

The Company is also progressing additional patent applications across key jurisdictions, including the US, covering proprietary formulations, treatment methods, biomarker-guided dosing and indication-specific applications, including Binge Eating Disorder and Irritable Bowel Syndrome.

Collectively, the expanding portfolio provides multiple layers of potential IP protection around TRP-8803, strengthening Entropy's competitive position and supporting its long-term clinical development, commercialisation and strategic partnering objectives.

The South African patent has a term of 20 years from 12 September 2023, subject to applicable renewal fees, providing protection through to 2043.

Management commentary:

CEO, Mr Jason Carroll, said: *"The grant of our South African patent represents another positive step in expanding our international IP portfolio, following the successful grant of our corresponding Australian patent earlier this year.*

"Our IP strategy is focused on building a broad and defensible portfolio that protects multiple aspects of our proprietary psilocin technology, from formulation and delivery through to dosing methodologies and therapeutic applications. By securing protection across these complementary areas, we are seeking to establish meaningful barriers to entry and strengthen our competitive position as we advance TRP-8803 towards commercialisation.

"With patents now granted in Australia and South Africa, and additional applications progressing across key international jurisdictions, we are systematically building a global IP portfolio designed to support the long-term commercial potential of TRP-8803. Importantly, this approach also strengthens our position in future licensing and strategic partnership discussions, while providing the flexibility to pursue opportunities across multiple therapeutic indications."

This announcement has been authorised by the Board of Entropy Neurodynamics Limited.

– ENDS –

INVESTOR & MEDIA CONTACT

Jason Carroll
Chief Executive Officer
Entropy Neurodynamics Limited
jcarroll@tryptherapeutics.com

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Entropy Neurodynamics Limited

Entropy Neurodynamics is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The Company's lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe. Development of TRP-8803 follows a number of Phase 2a clinical trials using oral psilocybin for the treatment of Binge Eating Disorder, Irritable Bowel Syndrome and Fibromyalgia. Results from each of these trials provided encouraging evidence of the potential clinical benefits of psychedelic therapy and will be used to further enhance the development of TRP-8803.

Register for updates

The Company encourages investors to register their details with the Automic Group investor portal. This also provides shareholders with the opportunity to elect communication methods to electronic only. This can be done via the following steps:

- *Go to investor.automic.com.au*
- *If you're an existing user, log in with your username and password.*
- *If you're a new user, click 'register', select 'Entropy Neurodynamics Limited'. Enter your Holding Number and postcode of the registered address on your holding. If your address is outside Australia, select the country. Follow the prompts to set up a username and password.*
- *Once you have created your account, you will need to update your communication method by clicking 'my details' under the 'profile' section of the investor portal account, then navigating to 'communication preferences' and selecting 'electronic only'.*

Risks associated with Psilocin

All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient's individual circumstances and medical history before proceeding. Adverse effects of psilocybin and similar compounds, such as psilocin, can include a temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. These effects of psilocybin and its derivatives are unlikely at low doses and in the treatment regimen used in psychedelic-assisted psychotherapy and appropriately managed in a controlled environment with direct medical supervision.

Forward-Looking Information

Certain information in this news release constitutes forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates and projections regarding future events. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Entropy Neurodynamics as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors

described in greater detail in the "Risk Factors" section of the Company's Replacement Prospectus available at www.asx.com.au. These factors are not intended to represent a complete list of the factors that could affect Entropy Neurodynamics; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.